The pace of public company financings by cell and gene therapy developers slowed in the first quarter versus the prior two years, according to a new report from the Alliance for Regenerative Medicine (ARM), but venture capital financings and partnership deals in the sector are maintaining a brisk pace so far in 2019.
ARM's quarterly report, based on data from Informa Pharma Intelligence, noted that cell and gene therapy IPO activity totaled just...






